Gyre Therapeutics, Inc. (GYRE)

Gyre Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022
Revenue	111.59	113.45	102.29
Revenue Growth (YoY)	-1.63%	10.91%	-
Cost of Revenue	4.18	4.64	4.79
Gross Profit	107.4	108.81	97.5
Selling, General & Admin	75.38	75.82	71.61
Research & Development	13.11	13.78	16.69
Operating Expenses	88.5	89.6	88.29
Operating Income	18.91	19.21	9.2
Interest & Investment Income	1.29	1.04	0.73
Earnings From Equity Investments	-1.31	-1.31	-0.25
Currency Exchange Gain (Loss)	-1.5	-1.5	-4.9
Other Non Operating Income (Expenses)	-2.44	-8.97	3.73
EBT Excluding Unusual Items	14.94	8.48	8.51
Gain (Loss) on Sale of Assets	-3.41	-3.34	-
Other Unusual Items	1	1	0.9
Pretax Income	-70.57	-76.97	9.41
Income Tax Expense	8.42	8.52	5.1
Earnings From Continuing Operations	-78.99	-85.48	4.31
Minority Interest in Earnings	-6.98	-7.45	-2.01
Net Income	-85.97	-92.93	2.3
Net Income to Common	-85.97	-92.93	2.3
Shares Outstanding (Basic)	76	66	64
Shares Outstanding (Diluted)	76	66	76
Shares Change (YoY)	19.88%	-13.02%	-
EPS (Basic)	-1.13	-1.41	0.04
EPS (Diluted)	-1.22	-1.41	0.03
Free Cash Flow	2.35	17.38	5.69
Free Cash Flow Per Share	0.03	0.26	0.08
Gross Margin	96.25%	95.91%	95.31%
Operating Margin	16.94%	16.94%	9.00%
Profit Margin	-77.04%	-81.92%	2.25%
Free Cash Flow Margin	2.10%	15.32%	5.56%
EBITDA	20.08	20.33	10.33
EBITDA Margin	18.00%	17.92%	10.10%
D&A For EBITDA	1.17	1.11	1.13
EBIT	18.91	19.21	9.2
EBIT Margin	16.94%	16.94%	9.00%
Effective Tax Rate	-	-	54.16%

Source: S&P Capital IQ. Standard template. Financial Sources.